Kinomica to Present AML Multi-drug Biomarker Research at 2024 ASCO Annual Meeting

LONDON, May 29, 2024 — Kinomica Ltd., a prominent developer of precision oncology diagnostics, has announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, from May 31 to June 4, 2024. The company will introduce data on a novel multi-drug biomarker signature designed to predict the most effective first-line treatments for newly diagnosed acute myeloid leukemia (AML) patients.

AML is a complex and varied cancer with generally poor outcomes. Although multiple therapies have been approved for AML, current patient stratification methods often yield inaccurate results in determining treatment eligibility. This challenge underscores the need for more precise diagnostic tools. Arran Dokal, PhD, the Chief Technology Officer of Kinomica, emphasized the importance of the new approach, stating, “AML is a heterogeneous malignancy with poor prognosis. Several treatments are approved for AML, but clinical trials have shown that current stratification approaches to determine patients' eligibility produce false positives and negatives. Here, we used phosphoproteomics to build signatures that accurately predict which of the approved therapies — venetoclax plus azacitidine, intensive chemotherapy (IC), or IC plus midostaurin — may be more efficacious for a given patient.”

The presentation titled "Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML)" will be delivered by Pedro Rodriguez Cutillas from Barts Cancer Institute. The poster session will take place on Monday, June 3, 2024, from 9:00 AM to 12:00 PM CDT. The presentation is part of the Hematologic Malignancies session, specifically focusing on leukemia, myelodysplastic syndromes, and allotransplant. The poster will be displayed at board number 84, and the abstract associated with this presentation is numbered 6525.

The study brought together contributions from a diverse group of researchers, including Pedro Rodriguez Cutillas, Weronika E. Borek, Josie A. Christopher, Luis Veiga Nobre, Amy Campbell, Janet Kelsall, Federico Pedicona, Nazrath Nawaz, David N. Perkins, Pedro Moreno Cardoso, Andrea Arruda, Alexander Joseph Ambinder, Sayantanee Dutta, Paolo Gallipoli, Heinz Sill, Gabriel Ghiaur, Mark D. Minden, Andrew Williamson, John G. Gribben, and Arran David Dokal. These experts are affiliated with prestigious institutions such as Barts Cancer Institute, Princess Margaret Cancer Centre, Johns Hopkins University, Medical University of Graz, and Kinomica Ltd.

Kinomica Ltd. specializes in precision oncology diagnostics and has developed the KScan® phosphoproteomic diagnostic platform. This tool helps clinicians leverage precision medicine by predicting which approved treatments will be the most effective for individual patients. This capability aims to significantly enhance clinical decision-making and patient outcomes in treating complex diseases like AML.

The company’s announcement of this significant advancement in AML treatment prediction reflects its ongoing commitment to improving cancer care through innovative diagnostic solutions. By presenting these findings at ASCO, Kinomica is poised to influence the future of AML treatment and potentially improve the prognosis for many patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!